Citadel Advisors’s Surface Oncology, Inc. Common Stock SURF Stock Holding History

Citadel Advisors’s Portfolio SURF Stock Details SURF Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-3,000	Closed	-$2.1K	–	15588
2023 Q1	$2.1K	Sell	3,000 -54,400	-95%	-$44.1K	﹤0.01%	14204
2022 Q4	$47.1K	Buy	57,400 +7,300	+15%	+$7.2K	﹤0.01%	12209
2022 Q3	$52K	Sell	50,100 -24,100	-32%	-$38.5K	﹤0.01%	11605
2022 Q2	$122K	Buy	74,200 +14,700	+25%	+$30.5K	﹤0.01%	11196
2022 Q1	$175K	Sell	59,500 -17,900	-23%	-$62.7K	﹤0.01%	11682
2021 Q4	$370K	Sell	77,400 -19,200	-20%	-$124K	﹤0.01%	10438
2021 Q3	$731K	Buy	96,600 +40,800	+73%	+$261K	﹤0.01%	8950
2021 Q2	$416K	Sell	55,800 -18,600	-25%	-$143K	﹤0.01%	10473
2021 Q1	$580K	Buy	74,400 +24,500	+49%	+$245K	﹤0.01%	9359
2020 Q4	$461K	Buy	49,900 +30,400	+156%	+$264K	﹤0.01%	8297
2020 Q3	$135K	Buy	+19,500	New	+$118K	﹤0.01%	9077

Other funds holding SURF

Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return

AVAI

Atlas Venture Associates IX Boston, Massachusetts $11.8M AUM 58.35% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

DCM

DAFNA Capital Management Los Angeles, California $524M AUM 164.42% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

YCM

Yakira Capital Management Westport, Connecticut $351M AUM 21.82% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

LCM

Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Citadel Advisors's SURF Position: Q2 2023 in Review

Citadel Advisors sold out of Surface Oncology, Inc. Common Stock (SURF) in Q2 2023, closing a stake of 118,652 shares — an estimated $82.9K sold.

Citadel Advisors first reported a position in SURF in Q2 2018 and held it in 18 quarters. The position peaked at $14.1M in Q2 2018. 61 funds tracked by Wall St. Rank hold SURF as of Q2 2023.

Citadel Advisors reported no remaining Surface Oncology, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
Citadel Advisors sold 118,652 Surface Oncology, Inc. Common Stock shares in Q2 2023, an estimated $82.9K.
Citadel Advisors first reported a position in Surface Oncology, Inc. Common Stock in Q2 2018 and held it in 18 quarters.
Citadel Advisors's Surface Oncology, Inc. Common Stock position peaked at $14.1M in Q2 2018.
61 funds tracked by Wall St. Rank held Surface Oncology, Inc. Common Stock as of Q2 2023.

Based on Citadel Advisors's 13F filing for Q2 2023, filed 14 Aug 2023.